[The world's first topical pan-JAK inhibitor for adults with moderate to severe chronic hand eczema is approved in China] On November 13, Leo Pharma announced that Delgo® (degotinib cream) has been approved by the China National Medical Products Administration for the topical treatment of adult patients with moderate to severe chronic hand eczema who have insufficient response to topical corticosteroid treatment or are not suitable for topical corticosteroid treatment. Delgo® is the world's first and currently only topical pan-JAK inhibitor (can act on JAK1, JAK2, JAK3, TYK2 simultaneously) for the treatment of moderate to severe chronic hand eczema in adults. This time it was approved in China, bringing new treatment options to patients who meet the indications.